Cantor Fitzgerald Reiterates Overweight on Akero Therapeutics, Maintains $69 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on Akero Therapeutics (NASDAQ:AKRO) and maintained a $69 price target.
October 04, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Akero Therapeutics and maintained a $69 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Akero Therapeutics. The maintained price target of $69 suggests that the analyst believes the stock has potential for growth. This could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100